9-氨基喜树碱
| 中文名称 | 9-氨基喜树碱 |
|---|---|
| 中文同义词 | 9-氨基喜树碱;(S)-10-氨基-4-乙基-4-羟基-1H-吡喃并[3',4':6,7]1-吲哚啉嗪O[1,2-B]喹啉-3,14(4H,12H)-二酮;9-氨基喜树碱,(20S)-9-氨基喜树碱;9-AMINOCAMPTOTHECIN 9-氨基喜树碱;9-氨基喜树碱 250MG;(20S)-9-氨基喜树碱;9-氨基喜树碱, >96%;9-氨基喜树碱 标准品 |
| 英文名称 | 9-Aminocamptothecin |
| 英文同义词 | 4':6,7)indolizino(1,2-B)quinoline-3,14(4H,12H)-dione;4':6,7)indolizino(1,2-B)quinoline-3,14(4H,12H)-dione, 10-amino-4-ethyl-4-hydroxy-, (S)-;CAMPTOTHECIN, 9-AMINO-(RG);(S)-10-AMino-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;(S)-10-Amino-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-di;CAMPTOTHECIN, 9-AMINO-;AMinocaMptothecin;9-AMINO-CAMPTOTHECIN |
| CAS号 | 91421-43-1 |
| 分子式 | C20H17N3O4 |
| 分子量 | 363.37 |
| EINECS号 | |
| 相关类别 | 化学连接;中药对照品;喜树碱系列;植物提取物;标准品;Pharmaceutical Raw Materials;Alkaloids;分析试剂标准品;细胞生物学试剂;对照品-中药对照品;对照品;标准品 -中药标准品;医药原料药;医药、农药及染料中间体;标准品，对照品;Natural Anti-cancer Medical Materials and It's Derivatives |
| Mol文件 | 91421-43-1.mol |
| 结构式 |  |
9-氨基喜树碱 性质
| 熔点 | 142.0-145.0 °C |
|---|---|
| 沸点 | 819.6±65.0 °C(Predicted) |
| 密度 | 1.55±0.1 g/cm3(Predicted) |
| 储存条件 | 2-8°C(protect from light) |
| 溶解度 | DMSO 中≤1mg/ml；二甲基甲酰胺中≤1mg/ml |
| 形态 | 粉末晶体 |
| 酸度系数(pKa) | 11.23±0.20(Predicted) |
| 颜色 | 淡黄色至黄色至橙色 |
| Merck | 14,431 |
| InChIKey | FUXVKZWTXQUGMW-FQEVSTJZSA-N |
| CAS 数据库 | 91421-43-1(CAS DataBase Reference) |
| Target | Value |
|
Topo I
() |
In human breast (MCF-7), bladder (MGH-U1), and colon (HT-29) cancer cell lines, 9-Aminocamptothecin cytotoxicity increases with both higher drug concentrations and longer exposure times. Minimal cell killing is also observed unless 9-Aminocamptothecin concentrations exceeds a threshold of 2.7 nm. 9-Aminocamptothecin inhibits PC-3, PC-3M, DU145, and LNCaP cells with IC 50 values of 34.1, 10, 6.5, and 8.9 nM, respectively after 96 h of drug exposure.
9-amino-CPT (9-amino-20(S)-camptothecin) inhibits tumor growth at the lowest oral dose (0.35 mg/kg/day), whereas higher oral doses (0.75 and 1 mg/kg/day) and s.c. administration (4 mg/kg/week) causes tumor regression. 9-amino-CPT (9-amino-20(S)-camptothecin) is well tolerated at all doses, with no toxic death or weight loss of more than 10% observed in any group. 9-amino-CPT (9-amino-20(S)-camptothecin) induces complete remissions in 55 % of SCID mice engrafted with human myeloid leukemia. The oral and intravenous routes are equally effective. The results with this pre-clinical model support the evaluation of 9-Aminocamptothecin as antileukemic agent in a phase I trial in patients with AML.
药理药效:抗肿瘤
安全信息
| RTECS号 | UQ0490500 |
|---|---|
| 海关编码 | 29349990 |